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Introduction
As the worldwide population ages, the population prevalence of
osteoporosis is also increasing. About 30% of postmenopausal
women in Europe and the United States have osteoporosis and
it is estimated that over 40% of postmenopausal women with
osteoporosis in Europe and the United States will experience
at least one fragility fracture (1).
A worldwide estimate for new osteoporotic fractures in 2000
was 9 million: in which 1.6 million hip, 1.7 million forearm, and
1.4 million clinical vertebral fractures (2).
In the U.S.A. non vertebral fractures represent approximately
75% of osteoporotic fractures and account for 90% of osteo-
porosis related costs (3).
With regard to Italy, on the basis of ESOPO study, estimates of
prevalent fracture among women aged 50-79 years are more
than 1.600.000 (ISTAT 2001 data on Italian population) (4).
Consistently with international data the non vertebral fractures
are most frequent type: 79% are non vertebral/non hip frac-
tures (wrist, ankle, humerus, tibial plate, etc.), 13% are verte-
bral and 8% are hip fractures.
Osteoporosis fractures result in increased future fracture risk;
after initial vertebral fracture, risk of subsequent, non-vertebral
fractures increases by 2-3-fold (1). Furthermore, after a verte-
bral fracture, 1 in 4 women will re-fracture during the following
year (5). Finally, postmenopausal women with a history of frac-
ture at any site should be considered for further evaluation and
treatment due to an approximate 2-fold increased risk of sub-
sequent fractures (6).
The most serious consequences of osteoporosis are femoral
fractures; from a clinical standpoint 24% of patient die within
one year from occurrence and only 15% are able to return to
unassisted ambulation (1) and 27% are forced to enter in nurs-
ing homes (7).
Impact of femur fractures is dramatic also from a social-eco-
nomic standpoint: with regard to Italian data, cost for hospital-
ization following a femur fracture is € 400 million/year; taking
into account also indirect costs (post-surgery rehabilitation,
etc.) expenditure is over € 1 billion/year, with a 15% yearly in-
crease trend (8). 
Economic burden is similar to that of myocardial infarction for
hospitalization rates and higher than that with regard to both di-
rect costs and growth trends (8).
Observational studies
Randomized controlled trials (RCTs) are the gold standard for
determining drug efficacy and safety. RCTs are designed to
minimize internal bias and to maximize treatment effect. How-
ever, RCT trial design creates shortfalls with regards to exter-
nal validity of the outcomes. 
Many patients with osteoporosis, however, cannot be included
in standard RCTs because of co-morbidities and prior thera-
pies, e.g. bone-active agents, steroids, etc. (9). Tightly con-
trolled protocols may produce outcomes more favourable than
in actual clinical practice (10). 
Furthermore, RCTs are not always predictive for adverse event
profile since the number of patients maybe too low to detect
low frequency events; enrollment criteria maybe too strict and
exclude high risk population; detailed patient instructions by
dedicated personal may minimize the risk of wrong intake and
there is limited follow-up.
The role of observational studies is to complement RCTs by
expanding the clinical evidence. Observational studies can
complement RCTs data of efficacy by demonstrating effective-
ness across a range of patients and health care practices by
showing that a drug indeed achieves its clinical effect in the re-
al world.
Healthcare database studies can help address many questions
such as insights into the disease; safety in actual clinical prac-
tice; treatment patterns; resource utilization and real world ef-
fectiveness - treatment comparisons. Examples include use of
the General Practitioners Research Database in the UK to
study risk of fracture after glucocorticoid use, comparative
statin safety assessment, and use of databases to study under-
diagnosis and treatment following fracture.
Over the past decade, large claims databases have become
very common in North America and Europe and are used to
conduct ‘effectiveness studies’. 
RCTs and observational studies have consistent results in
most cases; e.g. reduction in all causes of mortality following
statin use. However, there are limitations in the use of health-
care databases: chart review may not be available to validate
codes or identify coding errors; we cannot demonstrate causa-
tion of the event to the disease; we cannot assess use of non-
prescription  products. Selection bias is possible since not all
medical information is known and external variables are not
controlled.
REAL study
The REAL study was a retrospective, observational study
based on data retrieved from United States healthcare utiliza-
tion records including 101 health plans (11).
Patients were women ≥ 65 years old newly treated with once
weekly dosed risedronate (35 mg) or alendronate (35 or 70
mg). Patients prescribed bisphosphonates during 6 months be-
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fore index drug initiation were excluded to select only new bis-
phosphonate users.
Patients were monitored until one of the following occurred: 
– 12 months of bisphosphonate use
– Bisphosphonate discontinuation, switching, or 15-day gap in
treatment
– Incident, non traumatic non-vertebral fracture.
A total of 12.215 risedronate users were followed for a mean of
226 days, with 63% completing 12 months of evaluation;
21,615 alendronate users (8% with 35 mg and 92% with 70
mg) were followed for a mean of 238 days, with 67% complet-
ing 12 months of evaluation.
Risedronate patients were older, used more concomitant med-
ications, used more glucocorticoids, and had co-morbid
rheumatoid arthritis significantly more than alendronate users
(P ≤ 0.01).
These demographic differences suggest that the risedronate
cohort was at higher risk for subsequent fracture before treat-
ment initiation. 
Conversely, risedronate users had greater previous use of calci-
tonin or raloxifene, which may decrease fracture risk. In the six
and twelve months “historical period” before bisphosphonate ini-
tiation clinical diagnosis of non vertebral fracture was similar be-
tween subsequent risedronate and alendronate users, while pre-
vious hip fracture had occurred significantly more frequently
among patients later prescribed risedronate (P < 0.05).
Results
– During the 12 months of observation after the start of bis-
phosphonate therapy, 507 subjects had non vertebral frac-
tures. The site of non vertebral fracture was wrist (30%), hip
(21%), leg (17%), pelvis (15%), humerus (14%), and clavi-
cle (3%).
– Fracture incidence was similar during the first 3 months of
treatment. Fracture incidence was significantly lower with
risedronate after 6 months.
– Non-vertebral fracture incidence with risedronate was 19%
lower after 6 months and 18% lower after 12 months than
with alendronate.
– Hip fracture incidence with risedronate was 46% lower after 6
months and 43% lower after 12 months than with alen-
dronate.
Significant differences at 6 and 12 months persisted after ad-
justing analyses for adherence, baseline fracture, and demo-
graphics. Excluding the small minority of patients treated
with 35 mg alendronate also did not change outcome of
analyses.
Conclusions
The REAL study results are generalizable to the real world clin-
ical settings. Data were collected from more than 100 health
plans in 34 states, providing a broad sample of patients and
clinician practice patterns. 
Results of the REAL study are consistent with efficacy timing (6
and 12 months) in RCTs for both risedronate (12) and alen-
dronate (13).
As with all cohort studies, the interpretation of results may be
limited by the non-randomized nature of the study design.
However, these results are consistent with the results of analy-
ses of clinical trials and show that patients treated with rise-
dronate are better protected from non-vertebral and hip frac-
tures during their first year of therapy than those treated with
alendronate. 
Superior protection from risedronate begins after 6 months of
treatment initiation and leads to protection of more patients as
compared to alendronate.
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Figure 1 - Kaplan-Meier analysis for relative hip fractures incidence re-
duction.
12 months OR = 0.57 (p = 0.01, 95% CI: 13-63%)
